反応式
[O:1]=[C:2]1[C:11]([CH:12]2[CH2:17][CH2:16][N:15]([C:18]([O:20][CH:21]([CH2:36][C:37]3[CH:45]=[C:44]([CH3:46])[C:43]4[C:39](=[CH:40][N:41](COCC[Si](C)(C)C)[N:42]=4)[CH:38]=3)[C:22](=[O:35])[N:23]3[CH2:28][CH2:27][CH:26]([N:29]4[CH2:34][CH2:33][CH2:32][CH2:31][CH2:30]4)[CH2:25][CH2:24]3)=[O:19])[CH2:14][CH2:13]2)=[CH:10][C:9]2[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=2)[NH:3]1>FC(F)(F)C(O)=O>[O:1]=[C:2]1[C:11]([CH:12]2[CH2:13][CH2:14][N:15]([C:18]([O:20][CH:21]([CH2:36][C:37]3[CH:38]=[C:39]4[C:43](=[C:44]([CH3:46])[CH:45]=3)[NH:42][N:41]=[CH:40]4)[C:22](=[O:35])[N:23]3[CH2:24][CH2:25][CH:26]([N:29]4[CH2:30][CH2:31][CH2:32][CH2:33][CH2:34]4)[CH2:27][CH2:28]3)=[O:19])[CH2:16][CH2:17]2)=[CH:10][C:9]2[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=2)[NH:3]1参加物
3
実験手順
(±)-3-(7-Methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate (112 mg, 0.15 mmol) was dissolved in trifluoroacetic acid (50% in dichloromethane, 6 mL) and stirred at room temperature for 2 h. The reaction was concentrated and purified by column chromatography (5% methanol/dichloromethane to 7:93:1 methanol/dichloromethane/33% trimethylamine in ethanol) gave 89.6 mg (97%) as a white solid. Mass spec.: 755.37 (MH)+.
後処理
- concentrationThe reaction was concentrated
- custompurified by column chromatography (5% methanol/dichloromethane to 7:93:1 methanol/dichloromethane/33% trimethylamine in ethanol)
- customgave 89.6 mg (97%) as a white solid
出典と根拠
- ORDレコード
- ord-1e53113a29ca4194bb0627b3244d7ffa
- 出典データセット
- uspto-grants-2010_08
- 特許番号
- US07772244B2
関連ノート
読み込み中…